Výsledky vyhledávání - "J H, Schellens"

Influence of dose and infusion duration on pharmacokinetics of ifosfamide and metabolites

Autor: T, Kerbusch, R A, Mathôt, H J, Keizer, G P, Kaijser, J H, Schellens, J H, Beijnen

Publikováno v: Drug metabolism and disposition: the biological fate of chemicals. 29(7)

The anticancer drug ifosfamide is a prodrug requiring activation through 4-hydroxyifosfamide to ifosforamide mustard, to exert cytotoxicity. Deactivation of ifosfamide leads to 2- and 3-dechloroethylifosfamide and the release of potentially neurotoxi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::dc9f337fcfcf0feeb64943b7a735f412
https://pubmed.ncbi.nlm.nih.gov/11408362

Zobrazit plný text záznamu

Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918

Autor: M, Maliepaard, M A, van Gastelen, A, Tohgo, F H, Hausheer, R C, van Waardenburg, L A, de Jong, D, Pluim, J H, Beijnen, J H, Schellens

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research. 7(4)

This study was aimed at characterizing the role of BCRP/MXR/ABCP (BCRP) in resistance of the human ovarian tumor cell lines T8 and MX3 to camptothecins more extensively and investigating whether resistance can be reversed by inhibiting BCRP by GF1209

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::69a01d6f5c500325798340dae24df5c4
https://pubmed.ncbi.nlm.nih.gov/11309344

Zobrazit plný text záznamu

Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues

Autor: M, Maliepaard, G L, Scheffer, I F, Faneyte, M A, van Gastelen, A C, Pijnenborg, A H, Schinkel, M J, van De Vijver, R J, Scheper, J H, Schellens

Publikováno v: Cancer research. 61(8)

High expression of the Breast Cancer Resistance Protein (BCRP) gene has been shown to be involved in resistance to chemotherapeutic drugs. Knowledge of the localization of BCRP protein in normal tissues may help unravel the normal function of this pr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::74473d331836774a0391c8874ee46579
https://pubmed.ncbi.nlm.nih.gov/11309308

Zobrazit plný text záznamu

Population pharmacokinetics of thioTEPA and its active metabolite TEPA in patients undergoing high-dose chemotherapy

Autor: A D, Huitema, R A, Mathôt, M M, Tibben, J H, Schellens, S, Rodenhuis, J H, Beijnen

Publikováno v: British journal of clinical pharmacology. 51(1)

To study the population pharmacokinetics of thioTEPA and its main metabolite TEPA in patients receiving high-dose chemotherapy consisting of thioTEPA (80-120 mg x m(-2) x day(-1)), cyclophosphamide (1000-1500 mg x m(-2) x day(-1)) and carboplatin (26

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::9c91e42fa9afdcaa4bc1194f6026f51e
https://pubmed.ncbi.nlm.nih.gov/11167666

Zobrazit plný text záznamu

Pharmacokinetics and pharmacodynamics of the novel marine-derived anticancer agent ecteinascidin 743 in a phase I dose-finding study

Autor: C, van Kesteren, E, Cvitkovic, A, Taamma, L, López-Lázaro, J M, Jimeno, C, Guzman, R A, Math t, J H, Schellens, J L, Misset, E, Brain, M J, Hillebrand, H, Rosing, J H, Beijnen

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research. 6(12)

Ecteinascidin (ET) 743 is an anticancer agent derived from the Caribbean tunicate Ecteinascidia turbinata. Preclinical studies revealed activity of ET-743 against different tumor types. A Phase I clinical trial was designed with ET-743 to identify th

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::d4da3160c154dfea0521067505e79acc
https://pubmed.ncbi.nlm.nih.gov/11156226

Zobrazit plný text záznamu

Increased oral bioavailability of paclitaxel by GF120918 in mice through selective modulation of P-glycoprotein

Autor: H A, Bardelmeijer, J H, Beijnen, K R, Brouwer, H, Rosing, W J, Nooijen, J H, Schellens, O, van Tellingen

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research. 6(11)

Previous studies in mice with disrupted mdr1a P-glycoprotein genes have shown that the oral bioavailability of paclitaxel is very low because of the presence of this drug-transporting protein in the intestinal wall. Additional studies with cyclospori

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::0c2466ac72094e0cdee797e3be778e1b
https://pubmed.ncbi.nlm.nih.gov/11106262

Zobrazit plný text záznamu

Evaluation of the autoinduction of ifosfamide metabolism by a population pharmacokinetic approach using NONMEM

Autor: T, Kerbusch, A D, Huitema, J, Ouwerkerk, H J, Keizer, R A, Mathôt, J H, Schellens, J H, Beijnen

Publikováno v: British journal of clinical pharmacology. 49(6)

This study investigated the population pharmacokinetics of ifosfamide in 15 patients treated for soft tissue sarcoma with 9 or 12 g m-2 ifosfamide by means of a 72 h continuous i.v. infusion.A model was developed using nonlinear mixed effects modelli

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::e88edd5070425a9c6baaf2c18bd87ec4
https://pubmed.ncbi.nlm.nih.gov/10848719

Zobrazit plný text záznamu

Breast cancer resistance protein is localized at the plasma membrane in mitoxantrone- and topotecan-resistant cell lines

Autor: G L, Scheffer, M, Maliepaard, A C, Pijnenborg, M A, van Gastelen, M C, de Jong, A B, Schroeijers, D M, van der Kolk, J D, Allen, D D, Ross, P, van der Valk, W S, Dalton, J H, Schellens, R J, Scheper

Publikováno v: Cancer research. 60(10)

Tumor cells may display a multidrug resistant phenotype by overexpression of ATP-binding cassette transporters such as multidrug resistance (MDRI) P-glycoprotein, multidrug resistance protein 1 (MRP1), and breast cancer resistance protein (BCRP). The

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::1813380e63045c31cdfc3ce59d7717d6
https://pubmed.ncbi.nlm.nih.gov/10825126

Zobrazit plný text záznamu

Successful treatment with paclitaxel of a patient with metastatic extra-adrenal pheochromocytoma (paraganglioma). A case report and review of the literature

Autor: C M, Kruijtzer, J H, Beijnen, M, Swart, J H, Schellens

Publikováno v: Cancer chemotherapy and pharmacology. 45(5)

This case report describes the history of a patient with an aggressive course of a metastatic extra-adrenal pheochromocytoma (paraganglioma) who received different combination chemotherapy regimens with no or short-lasting clinical benefit. However,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::8e6c772afbe2905340b7ef130908156a
https://pubmed.ncbi.nlm.nih.gov/10803928

Zobrazit plný text záznamu

Coadministration of oral cyclosporin A enables oral therapy with paclitaxel

Autor: J M, Meerum Terwogt, M M, Malingré, J H, Beijnen, W W, ten Bokkel Huinink, H, Rosing, F J, Koopman, O, van Tellingen, M, Swart, J H, Schellens

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research. 5(11)

i.v. paclitaxel is inconvenient and associated with significant and poorly predictable side effects largely due to the pharmaceutical vehicle Cremophor EL. Oral administration may be attractive because it may circumvent the use of Cremophor EL. Howev

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::b9891d35e4bd0bb594a0ae0108b86cf7
https://pubmed.ncbi.nlm.nih.gov/10589748

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání